Question

Difficulty: HardGynecologic Infections

A 24-year-old woman is evaluated in the outpatient clinic for persistent vaginal discharge and vulvar pruritus. Three weeks ago, she presented with a copious, malodorous, yellow-green vaginal discharge and was diagnosed with a vaginal infection. At that time, she was treated with a single 2-gram dose of oral metronidazole. She reports that her symptoms improved for a few days but subsequently returned to their initial severity. The patient is in a monogamous relationship; her male partner was simultaneously treated with a single 2-gram dose of oral metronidazole, and they abstained from sexual activity for 10 days following treatment. Vital signs are within normal limits. Pelvic examination reveals a frothy, yellowish-green vaginal pooling and diffuse punctate hemorrhages on the exocervix. The vaginal pH is 6.5. Microscopic evaluation of a saline wet mount demonstrates numerous polymorphonuclear leukocytes and motile, flagellated organisms slightly larger than white blood cells. Which of the following is the most appropriate next step in pharmacotherapy for this patient?

  1. A 7-day course of oral metronidazoleAnswer
  2. B
    A 5-day course of intravaginal metronidazole gel
  3. C
    Repeat the single 2-gram dose of oral metronidazole
  4. D
    A single 150-mg oral dose of fluconazole
  5. E
    Intramuscular ceftriaxone and a 7-day course of oral doxycycline

Answer

A 7-day course of oral metronidazole
The correct answer is a 7-day course of oral metronidazole. This patient presents with classic signs of trichomoniasis, including a frothy, yellow-green discharge, colpitis macularis ('strawberry cervix'), and motile flagellated protozoa on a saline wet mount. She was previously treated with a single 2-gram dose of oral metronidazole, which was historically the standard of care but is now known to have higher failure rates in women. Because her partner was treated simultaneously and they abstained from intercourse, reinfection is unlikely, pointing to treatment failure. Current guidelines recommend oral metronidazole 500 mg twice daily for 7 days as the first-line treatment for trichomoniasis in all women, and it is the specific recommended next step for patients who fail the single-dose regimen.

Step-by-Step Solution

1
Identify the causative pathogen based on clinical and microscopic findings.
The pathogen is Trichomonas vaginalis.
The presentation of frothy yellow-green discharge, punctate cervical hemorrhages (colpitis macularis or strawberry cervix), elevated pH, and motile flagellated organisms is pathognomonic for trichomoniasis.
2
Evaluate the initial treatment and determine the likelihood of reinfection.
The clinical picture represents treatment failure rather than reinfection.
The patient received an older single-dose regimen. Because her partner was treated concurrently and they maintained strict abstinence, reinfection is highly unlikely.
3
Determine the appropriate management for treatment failure of a single-dose regimen in a female patient.
A 7-day course of oral metronidazole.
Current clinical guidelines mandate multi-day dosing as first-line for women, and specifically recommend the 7-day oral regimen for those failing an initial single-dose approach.

Key Concept

Women with Trichomonas vaginalis who experience treatment failure after a single 2-gram dose of metronidazole, and in whom reinfection is excluded, should be treated with a 7-day course of oral metronidazole.
Rate this question